The rate limiting steps in the Cancer Immunity Cycle are the capture of cancer antigens by Dendritic Cells (DCs) and their presentation to tumour-antigen specific, naive T-cells which results in their activation to become effector (killer) cytotoxic T-cells (CTLs) able to eliminate tumour cells.

Ci's approach sidesteps these rate limiting steps, by fusing    tumour cells from the patient's cancer directly to their own DCs. Fusions thus puts all these tumour antigens directly into DCs and thereby enables efficient activation of ALL the naive T-cells that recognise these antigens into CTLs. Killing of target tumour cells by these CTLs results in immunogenic cell death of these cancer cells, further harnessing the cancer immunity cycle to eliminates the tumour and any metatases.